

# SOUTH CAROLINA ONCOLOGY SOCIETY

**President:**

Neal Christiansen, M.D.  
Charleston

March 14, 2011

**President-Elect:**

Jeffrey K. Giguere, M.D.  
Greenville

The Honorable James E. Clyburn  
2135 Rayburn House Office Building  
Washington, DC 20515

**Secretary/Treasurer:**

Kashyap B. Patel, M.D.  
Rock Hill

**RE: S. 296 and Shortages of Chemotherapeutics and Related  
Drugs for Cancer Treatment**

**Immediate Past-President:**

Elizabeth Christian, M.D.  
Charleston

Dear Representative Clyburn:

**Directors at Large:**

James D. Bearden, M.D., F.A.C.P.  
Spartanburg

Lawrence B. Holt, M.D.  
Myrtle Beach

Terence N. Moore, M.D.  
Charleston

Robert Smith, M.D.  
Columbia

The South Carolina Oncology Society (SCOS), which represents cancer care providers across the State, requests your attention to the important issue of drug shortages affecting many cancer patients. Certain oncology therapies are in short supply in South Carolina and across the country, forcing providers to alter or forgo needed treatments for providing quality care to patients with cancer.

There are many drugs facing manufacturing shortage, but the therapies most problematic to oncology are: **Leucovorin, Doxorubicin, Vincristine, Etoposide, Cisplatin, and Cytarabine.** While SCOS has learned that some of these drugs will become available later this year, some manufacturers have not been forthcoming with a timeline for many of the cancer-related therapies on this list.

Providers are generally not warned of the upcoming stoppages and are left to deal with not only the clinical implications for their patients, but also with the responsibility of reporting these shortages to the U.S. Food and Drug Administration (FDA). Since many treatment regimens are time sensitive, this process increases frustration and prohibits doctors and other providers from adequately preparing for a disruption in availability. This is troublesome to SCOS, and we have communicated our concerns to the manufacturers.

To help oncologists best serve cancer patients, SCOS requests any assistance your office can provide, including writing letters to manufacturers, distributors, and the FDA. Additionally, Senator Klobuchar recently introduced the *Preserving Access to Life-Saving Medications Act* (S. 296), for which SCOS requests your support. This bill requires manufacturers to report impending manufacturing stoppages to the FDA, hopefully discouraging unnecessary shortages in the future. While this legislation does not solve all of the problems associated with drug scarcity, it is a step in the right direction. Please assist cancer patients in South Carolina by considering our requests.

The Honorable James E. Clyburn  
March 14, 2011  
Page 2

Drug shortages are a continuing problem for your constituents. Any assistance you can provide is greatly appreciated. Please feel free to contact me for more information.

Sincerely,

A handwritten signature in black ink, appearing to read "Neal Christiansen". The signature is written in a cursive style and is positioned above the printed name.

Neal Christiansen, MD  
President

cc: Teva Pharmaceuticals; Attn:  
Leucovorin/Doxorubicin/Vincristine/Etoposide/Cisplatin Department;  
Jeffrey Herzfield, Senior VP and General Manager, Teva Health Systems;  
1090 Horsham Road; PO #1090; North Wales, PA 19454

Hospira Pharmaceuticals; Christopher B. Begley, Chairman and Chief  
Executive Officer; 275 North Field Drive; Lake Forest, Illinois 60045

APP Pharmaceuticals; John Ducker, Chief Executive Officer and  
President; 1501 East Woodfield Road, Suite 300 East; Schaumburg,  
IL 60173-5837

David Gaugh, VP and General Manager of Bedford Labs; 300 Northfield  
Road; Bedford, OH 44146

LCDR Valerie Jensen; Drug Shortage Project Manager; Center for Drug  
Evaluation and Research; Food and Drug Administration; 5600 Fishers  
Lane; Rockville, MD 20857

Mark J. Goldberger, MD, MPh; Drug Shortage Coordinator; Center for  
Drug Evaluation and Research; Food and Drug Administration; 5600  
Fishers Lane; Rockville, MD 20857

# SOUTH CAROLINA ONCOLOGY SOCIETY

**President:**

Neal Christiansen, M.D.  
Charleston

March 14, 2011

**President-Elect:**

Jeffrey K. Giguere, M.D.  
Greenville

The Honorable Jeff Duncan  
116 Canon House Office Building  
Washington, DC 20515

**Secretary/Treasurer:**

Kashyap B. Patel, M.D.  
Rock Hill

**RE: S. 296 and Shortages of Chemotherapeutics and Related  
Drugs for Cancer Treatment**

**Immediate Past-President:**

Elizabeth Christian, M.D.  
Charleston

Dear Representative Duncan:

**Directors at Large:**

James D. Bearden, M.D., F.A.C.P.  
Spartanburg

Lawrence B. Holt, M.D.  
Myrtle Beach

Terence N. Moore, M.D.  
Charleston

Robert Smith, M.D.  
Columbia

The South Carolina Oncology Society (SCOS), which represents cancer care providers across the State, requests your attention to the important issue of drug shortages affecting many cancer patients. Certain oncology therapies are in short supply in South Carolina and across the country, forcing providers to alter or forgo needed treatments for providing quality care to patients with cancer.

There are many drugs facing manufacturing shortage, but the therapies most problematic to oncology are: **Leucovorin, Doxorubicin, Vincristine, Etoposide, Cisplatin, and Cytarabine.** While SCOS has learned that some of these drugs will become available later this year, some manufacturers have not been forthcoming with a timeline for many of the cancer-related therapies on this list.

Providers are generally not warned of the upcoming stoppages and are left to deal with not only the clinical implications for their patients, but also with the responsibility of reporting these shortages to the U.S. Food and Drug Administration (FDA). Since many treatment regimens are time sensitive, this process increases frustration and prohibits doctors and other providers from adequately preparing for a disruption in availability. This is troublesome to SCOS, and we have communicated our concerns to the manufacturers.

To help oncologists best serve cancer patients, SCOS requests any assistance your office can provide, including writing letters to manufacturers, distributors, and the FDA. Additionally, Senator Klobuchar recently introduced the *Preserving Access to Life-Saving Medications Act* (S. 296), for which SCOS requests your support. This bill requires manufacturers to report impending manufacturing stoppages to the FDA, hopefully discouraging unnecessary shortages in the future. While this legislation does not solve all of the problems associated with drug scarcity, it is a step in the right direction. Please assist cancer patients in South Carolina by considering our requests.

The Honorable Jeff Duncan  
March 14, 2011  
Page 2

Drug shortages are a continuing problem for your constituents. Any assistance you can provide is greatly appreciated. Please feel free to contact me for more information.

Sincerely,



Neal Christiansen, MD  
President

cc: Teva Pharmaceuticals; Attn:  
Leucovorin/Doxorubicin/Vincristine/Etoposide/Cisplatin Department;  
Jeffrey Herzfield, Senior VP and General Manager, Teva Health Systems;  
1090 Horsham Road; PO #1090; North Wales, PA 19454

Hospira Pharmaceuticals; Christopher B. Begley, Chairman and Chief  
Executive Officer; 275 North Field Drive; Lake Forest, Illinois 60045

APP Pharmaceuticals; John Ducker, Chief Executive Officer and  
President; 1501 East Woodfield Road, Suite 300 East; Schaumburg,  
IL 60173-5837

David Gaugh, VP and General Manager of Bedford Labs; 300 Northfield  
Road; Bedford, OH 44146

LCDR Valerie Jensen; Drug Shortage Project Manager; Center for Drug  
Evaluation and Research; Food and Drug Administration; 5600 Fishers  
Lane; Rockville, MD 20857

Mark J. Goldberger, MD, MPH; Drug Shortage Coordinator; Center for  
Drug Evaluation and Research; Food and Drug Administration; 5600  
Fishers Lane; Rockville, MD 20857

# SOUTH CAROLINA ONCOLOGY SOCIETY

**President:**

Neal Christiansen, M.D.  
Charleston

March 14, 2011

**President-Elect:**

Jeffrey K. Giguere, M.D.  
Greenville

The Honorable Trey Gowdy  
1237 Longworth House Office Building  
Washington, DC 20515

**Secretary/Treasurer:**

Kashyap B. Patel, M.D.  
Rock Hill

**RE: S. 296 and Shortages of Chemotherapeutics and Related  
Drugs for Cancer Treatment**

**Immediate Past-President:**

Elizabeth Christian, M.D.  
Charleston

Dear Representative Gowdy:

**Directors at Large:**

James D. Bearden, M.D., F.A.C.P.  
Spartanburg

Lawrence B. Holt, M.D.  
Myrtle Beach

Terence N. Moore, M.D.  
Charleston

Robert Smith, M.D.  
Columbia

The South Carolina Oncology Society (SCOS), which represents cancer care providers across the State, requests your attention to the important issue of drug shortages affecting many cancer patients. Certain oncology therapies are in short supply in South Carolina and across the country, forcing providers to alter or forgo needed treatments for providing quality care to patients with cancer.

There are many drugs facing manufacturing shortage, but the therapies most problematic to oncology are: **Leucovorin, Doxorubicin, Vincristine, Etoposide, Cisplatin, and Cytarabine.** While SCOS has learned that some of these drugs will become available later this year, some manufacturers have not been forthcoming with a timeline for many of the cancer-related therapies on this list.

Providers are generally not warned of the upcoming stoppages and are left to deal with not only the clinical implications for their patients, but also with the responsibility of reporting these shortages to the U.S. Food and Drug Administration (FDA). Since many treatment regimens are time sensitive, this process increases frustration and prohibits doctors and other providers from adequately preparing for a disruption in availability. This is troublesome to SCOS, and we have communicated our concerns to the manufacturers.

To help oncologists best serve cancer patients, SCOS requests any assistance your office can provide, including writing letters to manufacturers, distributors, and the FDA. Additionally, Senator Klobuchar recently introduced the *Preserving Access to Life-Saving Medications Act* (S. 296), for which SCOS requests your support. This bill requires manufacturers to report impending manufacturing stoppages to the FDA, hopefully discouraging unnecessary shortages in the future. While this legislation does not solve all of the problems associated with drug scarcity, it is a step in the right direction. Please assist cancer patients in South Carolina by considering our requests.

Drug shortages are a continuing problem for your constituents. Any assistance you can provide is greatly appreciated. Please feel free to contact me for more information.

Sincerely,



Neal Christiansen, MD  
President

cc: Teva Pharmaceuticals; Attn:  
Leucovorin/Doxorubicin/Vincristine/Etoposide/Cisplatin Department;  
Jeffrey Herzfield, Senior VP and General Manager, Teva Health Systems;  
1090 Horsham Road; PO #1090; North Wales, PA 19454

Hospira Pharmaceuticals; Christopher B. Begley, Chairman and Chief  
Executive Officer; 275 North Field Drive; Lake Forest, Illinois 60045

APP Pharmaceuticals; John Ducker, Chief Executive Officer and  
President; 1501 East Woodfield Road, Suite 300 East; Schaumburg,  
IL 60173-5837

David Gaugh, VP and General Manager of Bedford Labs; 300 Northfield  
Road; Bedford, OH 44146

LCDR Valerie Jensen; Drug Shortage Project Manager; Center for Drug  
Evaluation and Research; Food and Drug Administration; 5600 Fishers  
Lane; Rockville, MD 20857

Mark J. Goldberger, MD, MPH; Drug Shortage Coordinator; Center for  
Drug Evaluation and Research; Food and Drug Administration; 5600  
Fishers Lane; Rockville, MD 20857

# SOUTH CAROLINA ONCOLOGY SOCIETY

**President:**

Neal Christiansen, M.D.  
Charleston

March 14, 2011

**President-Elect:**

Jeffrey K. Giguere, M.D.  
Greenville

The Honorable Mick Mulvaney  
1004 Longworth House Office Building  
Washington, DC 20515

**Secretary/Treasurer:**

Kashyap B. Patel, M.D.  
Rock Hill

**RE: S. 296 and Shortages of Chemotherapeutics and Related  
Drugs for Cancer Treatment**

**Immediate Past-President:**

Elizabeth Christian, M.D.  
Charleston

Dear Representative Mulvaney:

**Directors at Large:**

James D. Bearden, M.D., F.A.C.P.  
Spartanburg

Lawrence B. Holt, M.D.  
Myrtle Beach

Terence N. Moore, M.D.  
Charleston

Robert Smith, M.D.  
Columbia

The South Carolina Oncology Society (SCOS), which represents cancer care providers across the State, requests your attention to the important issue of drug shortages affecting many cancer patients. Certain oncology therapies are in short supply in South Carolina and across the country, forcing providers to alter or forgo needed treatments for providing quality care to patients with cancer.

There are many drugs facing manufacturing shortage, but the therapies most problematic to oncology are: **Leucovorin, Doxorubicin, Vincristine, Etoposide, Cisplatin, and Cytarabine.** While SCOS has learned that some of these drugs will become available later this year, some manufacturers have not been forthcoming with a timeline for many of the cancer-related therapies on this list.

Providers are generally not warned of the upcoming stoppages and are left to deal with not only the clinical implications for their patients, but also with the responsibility of reporting these shortages to the U.S. Food and Drug Administration (FDA). Since many treatment regimens are time sensitive, this process increases frustration and prohibits doctors and other providers from adequately preparing for a disruption in availability. This is troublesome to SCOS, and we have communicated our concerns to the manufacturers.

To help oncologists best serve cancer patients, SCOS requests any assistance your office can provide, including writing letters to manufacturers, distributors, and the FDA. Additionally, Senator Klobuchar recently introduced the *Preserving Access to Life-Saving Medications Act* (S. 296), for which SCOS requests your support. This bill requires manufacturers to report impending manufacturing stoppages to the FDA, hopefully discouraging unnecessary shortages in the future. While this legislation does not solve all of the problems associated with drug scarcity, it is a step in the right direction. Please assist cancer patients in South Carolina by considering our requests.

The Honorable Mick Mulvaney  
March 14, 2011  
Page 2

Drug shortages are a continuing problem for your constituents. Any assistance you can provide is greatly appreciated. Please feel free to contact me for more information.

Sincerely,

A handwritten signature in black ink, appearing to read "Neal Christiansen". The signature is written in a cursive style with a large, stylized initial "N".

Neal Christiansen, MD  
President

cc: Teva Pharmaceuticals; Attn:  
Leucovorin/Doxorubicin/Vincristine/Etoposide/Cisplatin Department;  
Jeffrey Herzfield, Senior VP and General Manager, Teva Health Systems;  
1090 Horsham Road; PO #1090; North Wales, PA 19454

Hospira Pharmaceuticals; Christopher B. Begley, Chairman and Chief  
Executive Officer; 275 North Field Drive; Lake Forest, Illinois 60045

APP Pharmaceuticals; John Ducker, Chief Executive Officer and  
President; 1501 East Woodfield Road, Suite 300 East; Schaumburg,  
IL 60173-5837

David Gaugh, VP and General Manager of Bedford Labs; 300 Northfield  
Road; Bedford, OH 44146

LCDR Valerie Jensen; Drug Shortage Project Manager; Center for Drug  
Evaluation and Research; Food and Drug Administration; 5600 Fishers  
Lane; Rockville, MD 20857

Mark J. Goldberger, MD, MPH; Drug Shortage Coordinator; Center for  
Drug Evaluation and Research; Food and Drug Administration; 5600  
Fishers Lane; Rockville, MD 20857

# SOUTH CAROLINA ONCOLOGY SOCIETY

**President:**

Neal Christiansen, M.D.  
Charleston

March 14, 2011

**President-Elect:**

Jeffrey K. Giguere, M.D.  
Greenville

**Secretary/Treasurer:**

Kashyap B. Patel, M.D.  
Rock Hill

The Honorable Tim Scott  
1117 Longworth House Office Building  
Washington, DC 20515

**RE: S. 296 and Shortages of Chemotherapeutics and Related  
Drugs for Cancer Treatment**

**Immediate Past-President:**

Elizabeth Christian, M.D.  
Charleston

Dear Representative Scott:

**Directors at Large:**

James D. Bearden, M.D., F.A.C.P.  
Spartanburg

Lawrence B. Holt, M.D.  
Myrtle Beach

Terence N. Moore, M.D.  
Charleston

Robert Smith, M.D.  
Columbia

The South Carolina Oncology Society (SCOS), which represents cancer care providers across the State, requests your attention to the important issue of drug shortages affecting many cancer patients. Certain oncology therapies are in short supply in South Carolina and across the country, forcing providers to alter or forgo needed treatments for providing quality care to patients with cancer.

There are many drugs facing manufacturing shortage, but the therapies most problematic to oncology are: **Leucovorin, Doxorubicin, Vincristine, Etoposide, Cisplatin, and Cytarabine.** While SCOS has learned that some of these drugs will become available later this year, some manufacturers have not been forthcoming with a timeline for many of the cancer-related therapies on this list.

Providers are generally not warned of the upcoming stoppages and are left to deal with not only the clinical implications for their patients, but also with the responsibility of reporting these shortages to the U.S. Food and Drug Administration (FDA). Since many treatment regimens are time sensitive, this process increases frustration and prohibits doctors and other providers from adequately preparing for a disruption in availability. This is troublesome to SCOS, and we have communicated our concerns to the manufacturers.

To help oncologists best serve cancer patients, SCOS requests any assistance your office can provide, including writing letters to manufacturers, distributors, and the FDA. Additionally, Senator Klobuchar recently introduced the *Preserving Access to Life-Saving Medications Act* (S. 296), for which SCOS requests your support. This bill requires manufacturers to report impending manufacturing stoppages to the FDA, hopefully discouraging unnecessary shortages in the future. While this legislation does not solve all of the problems associated with drug scarcity, it is a step in the right direction. Please assist cancer patients in South Carolina by considering our requests.

The Honorable Tim Scott  
March 14, 2011  
Page 2

Drug shortages are a continuing problem for your constituents. Any assistance you can provide is greatly appreciated. Please feel free to contact me for more information.

Sincerely,



Neal Christiansen, MD  
President

cc: Teva Pharmaceuticals; Attn:  
Leucovorin/Doxorubicin/Vincristine/Etoposide/Cisplatin Department;  
Jeffrey Herzfield, Senior VP and General Manager, Teva Health Systems;  
1090 Horsham Road; PO #1090; North Wales, PA 19454

Hospira Pharmaceuticals; Christopher B. Begley, Chairman and Chief  
Executive Officer; 275 North Field Drive; Lake Forest, Illinois 60045

APP Pharmaceuticals; John Ducker, Chief Executive Officer and  
President; 1501 East Woodfield Road, Suite 300 East; Schaumburg,  
IL 60173-5837

David Gaugh, VP and General Manager of Bedford Labs; 300 Northfield  
Road; Bedford, OH 44146

LCDR Valerie Jensen; Drug Shortage Project Manager; Center for Drug  
Evaluation and Research; Food and Drug Administration; 5600 Fishers  
Lane; Rockville, MD 20857

Mark J. Goldberger, MD, MPH; Drug Shortage Coordinator; Center for  
Drug Evaluation and Research; Food and Drug Administration; 5600  
Fishers Lane; Rockville, MD 20857

# SOUTH CAROLINA ONCOLOGY SOCIETY

**President:**

Neal Christiansen, M.D.  
Charleston

March 14, 2011

**President-Elect:**

Jeffrey K. Giguere, M.D.  
Greenville

The Honorable Joe Wilson  
2229 Rayburn House Office Building  
Washington, DC 20515

**Secretary/Treasurer:**

Kashyap B. Patel, M.D.  
Rock Hill

**RE: S. 296 and Shortages of Chemotherapeutics and Related  
Drugs for Cancer Treatment**

**Immediate Past-President:**

Elizabeth Christian, M.D.  
Charleston

Dear Representative Wilson:

**Directors at Large:**

James D. Bearden, M.D., F.A.C.P.  
Spartanburg

Lawrence B. Holt, M.D.  
Myrtle Beach

Terence N. Moore, M.D.  
Charleston

Robert Smith, M.D.  
Columbia

The South Carolina Oncology Society (SCOS), which represents cancer care providers across the State, requests your attention to the important issue of drug shortages affecting many cancer patients. Certain oncology therapies are in short supply in South Carolina and across the country, forcing providers to alter or forgo needed treatments for providing quality care to patients with cancer.

There are many drugs facing manufacturing shortage, but the therapies most problematic to oncology are: **Leucovorin, Doxorubicin, Vincristine, Etoposide, Cisplatin, and Cytarabine.** While SCOS has learned that some of these drugs will become available later this year, some manufacturers have not been forthcoming with a timeline for many of the cancer-related therapies on this list.

Providers are generally not warned of the upcoming stoppages and are left to deal with not only the clinical implications for their patients, but also with the responsibility of reporting these shortages to the U.S. Food and Drug Administration (FDA). Since many treatment regimens are time sensitive, this process increases frustration and prohibits doctors and other providers from adequately preparing for a disruption in availability. This is troublesome to SCOS, and we have communicated our concerns to the manufacturers.

To help oncologists best serve cancer patients, SCOS requests any assistance your office can provide, including writing letters to manufacturers, distributors, and the FDA. Additionally, Senator Klobuchar recently introduced the *Preserving Access to Life-Saving Medications Act* (S. 296), for which SCOS requests your support. This bill requires manufacturers to report impending manufacturing stoppages to the FDA, hopefully discouraging unnecessary shortages in the future. While this legislation does not solve all of the problems associated with drug scarcity, it is a step in the right direction. Please assist cancer patients in South Carolina by considering our requests.

The Honorable Joe Wilson  
March 14, 2011  
Page 2

Drug shortages are a continuing problem for your constituents. Any assistance you can provide is greatly appreciated. Please feel free to contact me for more information.

Sincerely,



Neal Christiansen, MD  
President

cc: Teva Pharmaceuticals; Attn:  
Leucovorin/Doxorubicin/Vincristine/Etoposide/Cisplatin Department;  
Jeffrey Herzfield, Senior VP and General Manager, Teva Health Systems;  
1090 Horsham Road; PO #1090; North Wales, PA 19454

Hospira Pharmaceuticals; Christopher B. Begley, Chairman and Chief  
Executive Officer; 275 North Field Drive; Lake Forest, Illinois 60045

APP Pharmaceuticals; John Ducker, Chief Executive Officer and  
President; 1501 East Woodfield Road, Suite 300 East; Schaumburg,  
IL 60173-5837

David Gaugh, VP and General Manager of Bedford Labs; 300 Northfield  
Road; Bedford, OH 44146

LCDR Valerie Jensen; Drug Shortage Project Manager; Center for Drug  
Evaluation and Research; Food and Drug Administration; 5600 Fishers  
Lane; Rockville, MD 20857

Mark J. Goldberger, MD, MPH; Drug Shortage Coordinator; Center for  
Drug Evaluation and Research; Food and Drug Administration; 5600  
Fishers Lane; Rockville, MD 20857

# SOUTH CAROLINA ONCOLOGY SOCIETY

**President:**

Neal Christiansen, M.D.  
Charleston

March 14, 2011

**President-Elect:**

Jeffrey K. Giguere, M.D.  
Greenville

**Secretary/Treasurer:**

Kashyap B. Patel, M.D.  
Rock Hill

The Honorable Jim DeMint  
167 Russell Senate Office Building  
Washington, DC 20510

**RE: S. 296 and Shortages of Chemotherapeutics and Related  
Drugs for Cancer Treatment**

**Immediate Past-President:**

Elizabeth Christian, M.D.  
Charleston

Dear Senator DeMint:

**Directors at Large:**

James D. Bearden, M.D., F.A.C.P.  
Spartanburg

Lawrence B. Holt, M.D.  
Myrtle Beach

Terence N. Moore, M.D.  
Charleston

Robert Smith, M.D.  
Columbia

The South Carolina Oncology Society (SCOS), which represents cancer care providers across the State, requests your attention to the important issue of drug shortages affecting many cancer patients. Certain oncology therapies are in short supply in South Carolina and across the country, forcing providers to alter or forgo needed treatments for providing quality care to patients with cancer.

There are many drugs facing manufacturing shortage, but the therapies most problematic to oncology are: **Leucovorin, Doxorubicin, Vincristine, Etoposide, Cisplatin, and Cytarabine.** While SCOS has learned that some of these drugs will become available later this year, some manufacturers have not been forthcoming with a timeline for many of the cancer-related therapies on this list.

Providers are generally not warned of the upcoming stoppages and are left to deal with not only the clinical implications for their patients, but also with the responsibility of reporting these shortages to the U.S. Food and Drug Administration (FDA). Since many treatment regimens are time sensitive, this process increases frustration and prohibits doctors and other providers from adequately preparing for a disruption in availability. This is troublesome to SCOS, and we have communicated our concerns to the manufacturers.

To help oncologists best serve cancer patients, SCOS requests any assistance your office can provide, including writing letters to manufacturers, distributors, and the FDA. Additionally, Senator Klobuchar recently introduced the *Preserving Access to Life-Saving Medications Act* (S. 296), for which SCOS requests your support. This bill requires manufacturers to report impending manufacturing stoppages to the FDA, hopefully discouraging unnecessary shortages in the future. While this legislation does not solve all of the problems associated with drug scarcity, it is a step in the right direction. Please assist cancer patients in South Carolina by considering our requests.

Drug shortages are a continuing problem for your constituents. Any assistance you can provide is greatly appreciated. Please feel free to contact me for more information.

Sincerely,

A handwritten signature in black ink, appearing to read "Neal Christiansen". The signature is written in a cursive style with a large, stylized initial "N".

Neal Christiansen, MD  
President

cc: Teva Pharmaceuticals; Attn:  
Leucovorin/Doxorubicin/Vincristine/Etoposide/Cisplatin Department;  
Jeffrey Herzfield, Senior VP and General Manager, Teva Health Systems;  
1090 Horsham Road; PO #1090; North Wales, PA 19454

Hospira Pharmaceuticals; Christopher B. Begley, Chairman and Chief  
Executive Officer; 275 North Field Drive; Lake Forest, Illinois 60045

APP Pharmaceuticals; John Ducker, Chief Executive Officer and  
President; 1501 East Woodfield Road, Suite 300 East; Schaumburg,  
IL 60173-5837

David Gaugh, VP and General Manager of Bedford Labs; 300 Northfield  
Road; Bedford, OH 44146

LCDR Valerie Jensen; Drug Shortage Project Manager; Center for Drug  
Evaluation and Research; Food and Drug Administration; 5600 Fishers  
Lane; Rockville, MD 20857

Mark J. Goldberger, MD, MPH; Drug Shortage Coordinator; Center for  
Drug Evaluation and Research; Food and Drug Administration; 5600  
Fishers Lane; Rockville, MD 20857

# SOUTH CAROLINA ONCOLOGY SOCIETY

**President:**

Neal Christiansen, M.D.  
Charleston

March 14, 2011

**President-Elect:**

Jeffrey K. Giguere, M.D.  
Greenville

The Honorable Lindsey Graham  
290 Russell Senate Office Building  
Washington, DC 20510

**Secretary/Treasurer:**

Kashyap B. Patel, M.D.  
Rock Hill

**RE: S. 296 and Shortages of Chemotherapeutics and Related  
Drugs for Cancer Treatment**

**Immediate Past-President:**

Elizabeth Christian, M.D.  
Charleston

Dear Senator Graham:

**Directors at Large:**

James D. Bearden, M.D., F.A.C.P.  
Spartanburg

Lawrence B. Holt, M.D.  
Myrtle Beach

Terence N. Moore, M.D.  
Charleston

Robert Smith, M.D.  
Columbia

The South Carolina Oncology Society (SCOS), which represents cancer care providers across the State, requests your attention to the important issue of drug shortages affecting many cancer patients. Certain oncology therapies are in short supply in South Carolina and across the country, forcing providers to alter or forgo needed treatments for providing quality care to patients with cancer.

There are many drugs facing manufacturing shortage, but the therapies most problematic to oncology are: **Leucovorin, Doxorubicin, Vincristine, Etoposide, Cisplatin, and Cytarabine.** While SCOS has learned that some of these drugs will become available later this year, some manufacturers have not been forthcoming with a timeline for many of the cancer-related therapies on this list.

Providers are generally not warned of the upcoming stoppages and are left to deal with not only the clinical implications for their patients, but also with the responsibility of reporting these shortages to the U.S. Food and Drug Administration (FDA). Since many treatment regimens are time sensitive, this process increases frustration and prohibits doctors and other providers from adequately preparing for a disruption in availability. This is troublesome to SCOS, and we have communicated our concerns to the manufacturers.

To help oncologists best serve cancer patients, SCOS requests any assistance your office can provide, including writing letters to manufacturers, distributors, and the FDA. Additionally, Senator Klobuchar recently introduced the *Preserving Access to Life-Saving Medications Act* (S. 296), for which SCOS requests your support. This bill requires manufacturers to report impending manufacturing stoppages to the FDA, hopefully discouraging unnecessary shortages in the future. While this legislation does not solve all of the problems associated with drug scarcity, it is a step in the right direction. Please assist cancer patients in South Carolina by considering our requests.

The Honorable Lindsey Graham  
March 14, 2011  
Page 2

Drug shortages are a continuing problem for your constituents. Any assistance you can provide is greatly appreciated. Please feel free to contact me for more information.

Sincerely,

A handwritten signature in black ink, appearing to read "Neal Christiansen". The signature is written in a cursive style with a large, stylized initial "N".

Neal Christiansen, MD  
President

cc: Teva Pharmaceuticals; Attn:  
Leucovorin/Doxorubicin/Vincristine/Etoposide/Cisplatin Department;  
Jeffrey Herzfield, Senior VP and General Manager, Teva Health Systems;  
1090 Horsham Road; PO #1090; North Wales, PA 19454

Hospira Pharmaceuticals; Christopher B. Begley, Chairman and Chief  
Executive Officer; 275 North Field Drive; Lake Forest, Illinois 60045

APP Pharmaceuticals; John Ducker, Chief Executive Officer and  
President; 1501 East Woodfield Road, Suite 300 East; Schaumburg,  
IL 60173-5837

David Gaugh, VP and General Manager of Bedford Labs; 300 Northfield  
Road; Bedford, OH 44146

LCDR Valerie Jensen; Drug Shortage Project Manager; Center for Drug  
Evaluation and Research; Food and Drug Administration; 5600 Fishers  
Lane; Rockville, MD 20857

Mark J. Goldberger, MD, MPH; Drug Shortage Coordinator; Center for  
Drug Evaluation and Research; Food and Drug Administration; 5600  
Fishers Lane; Rockville, MD 20857